System and method for determining individualized medical intervention for a disease state
A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression.
1. A method of generating an individualized treatment report comprising:
(a) obtaining a biological tumor sample from an individual diagnosed with breast cancer, wherein the individual has undergone prior treatment for the breast cancer;
(b) providing a molecular profile for the individual by performing a molecular test for a group of target genes in the biological tumor sample, wherein the group of the target genes comprises EGFR, KIT, TOP1, MLH1, ESR1and PDGFRB;
(c) providing a list of altered target genes by comparing the molecular profile to a normal breast tissue reference for each of the group of target genes to identify altered target genes in the biological tumor sample that exhibit a change compared to their respective normal reference;
(d) accessing an electronic network comprising a drug database that contains information on possible drug therapy for the altered target genes to compile a list of possible drug therapies for treating the breast cancer; and
(e) generating a report that provides the molecular profile and the list of possible drug therapies for treating the breast cancer, thereby generating the individualized treatment report.
2. The method of claim 1 , further comprising compiling a list of possible clinical trials for the individual by accessing an electronic clinical trial database that contains information on possible clinical trials for a cancer having one or more of the altered target genes.
3. The method of claim 2 , wherein the individualized treatment report lists the possible clinical trials for the individual.
4. The method of claim 1 , wherein the network further comprises a computer readable protocol for an automated internet search to identify clinical trial data related to the drug therapies in the patient report.
5. The method of claim 4 , wherein the clinical trial data is housed in a clinical database that is linked to the drug database.
6. The method of claim 5 , wherein the clinical database comprises metadata corresponding to clinical annotations for clinical trial data thereby allowing integration of multiple clinical trials.
7. The method of claim 1 , wherein the drug database further comprises information on possible drug therapy for one or more gene selected from AR, BCL2, BRCA2, CCND1, DNMT3A, ERBB2, ESR1, HGF, KRAS, MLH1, MSH2, MYC, NFKBIA, PDGFRA, PTEN, RAF1, RARA, TP53, VHL.
8. The method of claim 1 , wherein the drug database further comprises information on possible drug therapy for one or more gene selected from ACE2, ADA, ADH1C, ADH4, AGT, AR, AREG, ASNS, BCL2, BRCA2, CA2, caveolin, CD33, CD52(CDW52), CDK2, CES2, DCK, DNMT1, DNMT3A, EGFR, ERBB2, ERCC3, EREG (Epiregulin), ESR1, folate receptor, FOLR1, FOLR2, FSHB, FSHPRH1, FSHR, GART, GNRH1, GNRHR1, GSTP1, HDAC1, HGF, HIF1A, HIG1, HSPCA, IL13RA1, IL2RA (CD25), KIT, LTB, Lymphotoxin Beta Receptor, MLH1, MS4A1(CD20), MSH2, Myc, NFKB1, NFKB2, NFKBIA, ODC1, OGFR, PDGFC, PDGFRA, PDGFRB, PGR (PR), POLA, PPARG, PPARGC1, PTEN, PTGS2(Cox-2), RAF1, RARA, RXRB, SPARC, SSTR1, TK1, TNF, TOP1, TOP2A, TOP2B, Topoisomerase II, TXN, TXNRD1, TYMS, VDR, VEGF, VEGFC, VHL, ZAP70.
9. The method of claim 1 , wherein the prior treatment comprises the standard-of-care treatment for the breast cancer.
10. The method of claim 1 , wherein the individual has not responded to any prior treatment for the breast cancer.
11. The method of claim 2 , wherein the clinical trial database is accessed over the electronic network.
12. The method of claim 1 , wherein the possible drug therapies for a cancer having one or more of the altered target genes comprise drug therapies that are capable of interacting with one or more of the altered target genes or a gene product thereof.
13. The method of claim 1 , wherein the individualized treatment report comprises a computer generated report.
14. The method of claim 13 , wherein the computer generated report is accessible over the electronic network.
15. The method of claim 13 , wherein the individualized treatment report is a printed report.